Article Abstract

Immune checkpoint inhibitors in esophagogastric adenocarcinoma: do the results justify the hype?

Authors: Megan Greally, Geoffrey Y. Ku


Immune checkpoint inhibitors have transformed treatment paradigms in several cancers, many of which were previously associated with a poor prognosis, including melanoma and lung cancer. Given the poor outcomes from treatment with chemotherapy and targeted therapies in this disease, there has been strong interest in the evaluation of immunotherapy.